Drug-loaded nanobots for transmucosal delivery to mucinous tumours

This project aims to enhance drug delivery in pseudomyxoma peritonei using nanobots loaded with Mitomycin C or Encorafenib to improve treatment efficacy and patient outcomes.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

Mucus is a defensive barrier that protects the underlying cells from pathogens and toxic compounds, although it also hinders the delivery of drugs whenever they are administered locally.

Background

There are different types of mucus-secreting tumours, such as pseudomyxoma peritonei (PMP), that could benefit from more efficient transmucosal delivery of anti-cancer drugs. PMP is a rare disease and the most mucinous tumour type, thus it will be used as a proof of concept for this project.

Characteristics of PMP

PMP is characterised by the production of abundant mucus in the peritoneal cavity and is treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, usually Mitomycin C. This approach has extended patient survival, but there is a significant proportion of recurrence, most probably due to the shielding effect of mucus. Therefore, there is an urgent need to offer new therapeutic strategies to PMP patients.

Research Developments

Recently, Dr. Palmer’s lab has established a collection of PMP patient-derived organoids and xenografts and has shown that some PMP patients present oncogenic BRAFV600E mutations, introducing a new druggable targeted mutation.

Project Aim

In this proposal, Dr. Sánchez’s lab (IBEC), in collaboration with Dr. Palmer’s research group (VHIO), aims to use nanobots able to overcome the mucus barrier that will be loaded with Mitomycin C or Encorafenib (BRAF inhibitor) to treat PMP.

Methodology

A comparative study will be performed to assess the treatment’s efficacy compared to the standard of care, and medical advice will be received from Dr. Élez (VHUH) to ensure the translation of the results to the clinic.

Conclusion

We believe that using this all-in-one system will certainly enhance the delivery and efficacy of the active therapeutic compound, thus potentially improving current treatments.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-10-2023
Einddatum31-3-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYApenvoerder
  • FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Mucinase-based innovative therapy to enhance cancer treatment

The MUC-BITE project aims to develop Nano-MUCase, a mucinase-nanobody conjugate, to enhance CRC drug efficacy by degrading mucin barriers, while assessing its commercial viability.

€ 150.000
ERC Starting...

Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy

This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.

€ 1.500.000
ERC Proof of...

Preclinical validation and market analysis of a microMESH implant for brain cancer eradication

The project aims to develop and validate a novel drug delivery implant, microMESH, for targeted chemo-immunotherapy in glioblastoma, enhancing treatment efficacy and patient outcomes.

€ 150.000
ERC Proof of...

Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response

This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.

€ 150.000
ERC Starting...

Breaching the protective cancer stroma with radiotherapy-responsive liposomes

This project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy.

€ 1.942.158

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

SupraTag

Een innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen.

€ 200.200
EIC Accelerator

FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY

MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.

€ 2.494.504
EIC Transition

Clinical readiness of a live biotherapeutic for treatment of Non-Small Cell Lung Cancer (NSCLC)

Pulmobiotics aims to develop PB_LC, an engineered Mycoplasma pneumoniae strain, to enhance immunotherapy for NSCLC patients by improving T cell infiltration and overcoming treatment resistance.

€ 1.881.875
EIC Pathfinder

2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.

€ 2.740.675
Mkb-innovati...

Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker

De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.

€ 20.000